CA3251002A1 - REMIBRUTINIB INTENDED FOR USE IN THE TREATMENT OF HIDRADENITIS SUPPURATIVE - Google Patents

REMIBRUTINIB INTENDED FOR USE IN THE TREATMENT OF HIDRADENITIS SUPPURATIVE

Info

Publication number
CA3251002A1
CA3251002A1 CA3251002A CA3251002A CA3251002A1 CA 3251002 A1 CA3251002 A1 CA 3251002A1 CA 3251002 A CA3251002 A CA 3251002A CA 3251002 A CA3251002 A CA 3251002A CA 3251002 A1 CA3251002 A1 CA 3251002A1
Authority
CA
Canada
Prior art keywords
lou064
treatment
patient
use according
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3251002A
Other languages
English (en)
French (fr)
Inventor
Souvik BHATTACHARYA
Bruno BIETH
Bruno CENNI
Gordon Graham
Michael Juhnke
Christian Loesche
Karin Rapp
Kim-Hien SIN
Jonas Benjamin ZIERER
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA3251002A1 publication Critical patent/CA3251002A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3251002A 2022-02-28 2023-02-27 REMIBRUTINIB INTENDED FOR USE IN THE TREATMENT OF HIDRADENITIS SUPPURATIVE Pending CA3251002A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263314572P 2022-02-28 2022-02-28
US63/314,572 2022-02-28
US202263369016P 2022-07-21 2022-07-21
US63/369,016 2022-07-21
PCT/IB2023/051787 WO2023161887A1 (en) 2022-02-28 2023-02-27 Remibrutinib for use in the treatment of hidradenitis suppurativa

Publications (1)

Publication Number Publication Date
CA3251002A1 true CA3251002A1 (en) 2023-08-31

Family

ID=85570288

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3251002A Pending CA3251002A1 (en) 2022-02-28 2023-02-27 REMIBRUTINIB INTENDED FOR USE IN THE TREATMENT OF HIDRADENITIS SUPPURATIVE

Country Status (11)

Country Link
US (1) US20250099465A1 (cg-RX-API-DMAC10.html)
EP (1) EP4486346A1 (cg-RX-API-DMAC10.html)
JP (2) JP7696006B2 (cg-RX-API-DMAC10.html)
KR (1) KR20240155278A (cg-RX-API-DMAC10.html)
CN (1) CN120617264A (cg-RX-API-DMAC10.html)
AU (1) AU2023225222A1 (cg-RX-API-DMAC10.html)
CA (1) CA3251002A1 (cg-RX-API-DMAC10.html)
IL (1) IL314205A (cg-RX-API-DMAC10.html)
MX (1) MX2024010392A (cg-RX-API-DMAC10.html)
TW (1) TW202342048A (cg-RX-API-DMAC10.html)
WO (1) WO2023161887A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250243170A1 (en) * 2024-01-26 2025-07-31 Novartis Ag Remibrutinib drug substance and drug product substantially free of nitrosamine impurity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
WO2017089985A1 (en) 2015-11-26 2017-06-01 Novartis Ag Diamino pyridine derivatives
WO2018055550A1 (en) 2016-09-23 2018-03-29 Novartis Ag Indazole compounds for use in tendon and/or ligament injuries
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
JP2022500408A (ja) * 2018-09-12 2022-01-04 デノボ バイオファーマ エルエルシー エンザスタウリンとbtkの阻害剤との組合せおよびその使用
CN113840821A (zh) * 2019-05-23 2021-12-24 诺华股份有限公司 Btk抑制剂的晶型
US12383556B2 (en) 2019-05-23 2025-08-12 Novartis Ag Methods of treating Sjögren's syndrome using a Bruton's tyrosine kinase inhibitor
FI3972604T3 (fi) 2019-05-23 2025-09-01 Novartis Ag Brutonin tyrosiinikinaasin estäjä käytettäväksi kroonisen spontaanin urtikarian hoidossa
CA3163850A1 (en) * 2020-01-08 2021-07-15 Principia Biopharma Inc. Topical pharmaceutical compositions comprising 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile
EP4284344A1 (en) 2021-01-26 2023-12-06 Novartis AG Pharmaceutical composition

Also Published As

Publication number Publication date
AU2023225222A1 (en) 2024-07-25
JP2025134747A (ja) 2025-09-17
MX2024010392A (es) 2024-09-06
IL314205A (en) 2024-09-01
EP4486346A1 (en) 2025-01-08
JP7696006B2 (ja) 2025-06-19
CN120617264A (zh) 2025-09-12
TW202342048A (zh) 2023-11-01
JP2024511938A (ja) 2024-03-18
WO2023161887A1 (en) 2023-08-31
US20250099465A1 (en) 2025-03-27
KR20240155278A (ko) 2024-10-28

Similar Documents

Publication Publication Date Title
RU2724339C2 (ru) Сенекривирок для лечения фиброза
RU2748549C2 (ru) Способ лечения почечно-клеточного рака с использованием n-(4-(6,7-диметоксихинолин-4-илокси)фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, (2s)-гидроксибутандиоата
CN106999593A (zh) 用于纤维化治疗的赛尼克韦罗组合疗法
JP2026048721A (ja) ヒトにおける固形腫瘍の処置のためのC.novyi
AU2020280272B2 (en) Methods of treating Chronic Spontaneous Urticaria using a Bruton's tyrosine kinase inhibitor
EP4313043A1 (en) Treatment of hidradenitis suppurativa with orismilast
AU2018209807B2 (en) Enhancers of cellular cannibalism for use to sensitize tumors to radiation therapy
JP2025134747A (ja) 化膿性汗腺炎の治療における使用のためのレミブルチニブ
CN121985949A (zh) 用于治疗溃疡性结肠炎的奥法莫德
KR20220088830A (ko) 비뇨기계암의 치료 방법
CN107405403A (zh) 用于治疗纤维化的塞尼克韦罗
JP7594124B2 (ja) Lou064を使用した治療の方法
EA051701B1 (ru) Ремибрутиниб для применения в лечении гнойного гидраденита
CN118742308A (zh) 用于在治疗化脓性汗腺炎中使用的雷米布鲁替尼
TW202539668A (zh) 使用索樂匹尼布處置免疫性血小板減少症的方法
Marren et al. THU0173 Pregnancy Outcomes in the Tofacitinib RA Safety Database Through April 2014
EA051816B1 (ru) Способы лечения с применением lou064
HK40126973A (zh) 治疗前列腺癌的方法
JP2021511380A (ja) 腫瘍増殖を抑制するためのミナプリンの使用
El Rakaawi et al. THU0397 Efficacy of pamidronate in children with osteogenesis imperfecta: An open prospective study

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240806

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250107

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250107

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250107

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250121

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250121

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250121

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250214

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251216

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251216